Five things for pharma marketers to know: Monday, June 19, 2017

Five things for pharma marketers to know: Monday, June 19, 2017

Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors

Five things for pharma marketers to know: Thursday, June 15, 2017

Five things for pharma marketers to know: Thursday, June 15, 2017

Google invests in European biotechs; hospitals that restrict sales-rep visits more likely to prescribe cheaper generics; AI could help doctors with new research

Five things for pharma marketers to know: Thursday, February 2, 2017

Five things for pharma marketers to know: Thursday, February 2, 2017

Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue

Five things for pharma marketers to know: Wednesday, July 29

Five things for pharma marketers to know: Wednesday, July 29

Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.

Merck will evaluate Keytruda cancer combo therapy

Merck will collaborate with Syndax to evaluate the pairing of an anti-PD-1 therapy in Keytruda with HDAC inhibitor entinostat.

23andMe will harness genetic research in new drug discovery unit

23andMe will harness genetic research in new drug discovery unit

The personal genetics company created a therapeutics group to extricate new drug targets from its research database.

Newly discovered ALS gene may lead to new drug targets

A research collaboration between medical centers, drugmaker Biogen Idec and a biotechnology institute have identified a gene that could lead to new drug targets for sporadic amyotrophic lateral sclerosis—or Lou Gehrig's disease.

MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics

MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics

The biotech exec speaks about the global launch of his firm's lead product, Duchenne drug Translarna.

Apotex challenges Amgen blockbuster Neulasta

Canadian firm presents FDA with its third biosimilar application.

Merck buys Swiss biotech

The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million